Barrierefreiheit    Kontakt MedUni Wien    Intranet    MedUni Wien - Shop    Universitätsbibliothek    Universitätsklinikum AKH Wien  
 
 
 
 
 


    International journal of radiation oncology, biology, physics. 2020 Aug 24. pii: S0360-3016(20)34139-0. doi: 10.1016/j.ijrobp.2020.08.044
    Persistence of late substantial patient-reported symptoms (LAPERS) after radiochemotherapy including image-guided adaptive brachytherapy for locally advanced cervical cancer: A report from the EMBRACE study.
    Vittrup AS1,  Tanderup K2,  Bentzen SM3,  Jensen NBK4,  Spampinato S5,  Fokdal LU6,  Lindegaard JC7,  Sturdza A8,  Schmid M9,  Segedin B10,  Jürgenliemk-Schulz IM11,  Bruheim K12,  Mahantshetty U13,  Haie-Meder C14,  Rai B15,  Cooper R16,  van der Steen-Banasik E17,  Sundset M18,  Huang F19,  Nout RA20,  Villafranca E21,  Van Limbergen E22,  Pieters BR23,  Tan LT24,  Lutgens LCHW25,  Hoskin P26,  Pötter R27,  Kirchheiner K28
    Author information
    Abstract

    PURPOSE: This report describes persistence of late substantial treatment-related patient-reported symptoms (LAPERS) in the multi-institutional XXX study on MR image-guided adaptive brachytherapy in locally advanced cervical cancer (LACC).

    MATERIALS AND METHODS: Patient-reported symptoms (EORTC-C30/CX24) and physician-assessed morbidity (CTCAEv.3.0) were assessed at baseline and regular time points during follow-up. Patients with sufficient EORTC follow-up (baseline and ≥3 late follow-ups) were analyzed. LAPERS events were defined as the presence of substantial EORTC symptoms ("quite a bit"/"very much") for at least half of assessments ("persistence") and progression beyond baseline condition ("treatment-related"). For each EORTC symptom, the ratio between LAPERS rates and crude incidence rates of substantial symptoms was calculated to represent the proportion of symptomatic patients with persisting symptoms. For 9 symptoms with corresponding EORTC/CTCAE assessment, the overlap of LAPERS and severe morbidity events (G3-5) was evaluated.

    RESULTS: Out of 1047 patients with EORTC available, 741 had sufficient follow-up for the LAPERS analyses. Median follow-up was 59 months (IQR 42-70). Across all symptoms, the proportion of patients with LAPERS events (LAPERS rates) was in median 4.6% (range: 0.0% vaginal bleeding - 20.4% tiredness). Urinary frequency, neuropathy, fatigue, insomnia, and menopausal symptoms revealed LAPERS rates of >10%. Vomiting, blood in stools, urinary pain/burning, and abnormal vaginal bleeding displayed LAPERS rates of <1%. In median, 19% of symptomatic patients (IQR 8.0-28.5%) showed persistent long-term symptoms (LAPERS events). In symptoms with corresponding EORTC/CTCAE assessment, 12% of LAPERS events were accompanied by a severe CTCAE event.

    CONCLUSION: Within this large cohort of LACC survivors, a subgroup of patients with persistent symptoms (LAPERS events) was identified. For symptoms with corresponding EORTC/CTCAE assessment, the vast majority of LAPERS events occurred in patients without corresponding severe physician-assessed morbidity. These findings emphasize the importance of distinguishing between transient and persisting symptoms in the aftercare of LACC survivors.


    Copyright © 2020 Elsevier Inc. All rights reserved.

    Publikations ID: 32853710
    Quelle: öffnen
     
    Drucken
     
    ccc_logo_en.gif
    ccc_logo_en.gif
    ccc_logo_en.gif

    Schnellinfo

     
     

    Featured

     
     
     
     
     
     
     
     
     
     
     
     
     
    © MedUni Wien |
     Impressum | Nutzungsbedingungen | Kontakt